Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)

被引:0
作者
van Lokven, T.
Kempcke, R.
Ziemssen, T.
Meergans, M.
机构
[1] Novartis Pharma GmbH, Nurnberg, Germany
[2] Karl Gustav Carus Univ Hosp, Dresden, Germany
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
P502
引用
收藏
页码:S213 / S214
页数:2
相关论文
empty
未找到相关数据